Till startsida
Sitemap
To content Read more about how we use cookies on gu.se

Viktor Sandblom

Doctoral student

Viktor Sandblom
Doctoral student
viktor.sandblom@gu.se

Postal Address: Su sahlgrenska, 41345 Göteborg
Visiting Address: Gula stråket su , Göteborg


Department of Radiation Physics at Institute of Clinical Sciences (More Information)
Sahlgrenska Universitetssjukhuset
413 45 Göteborg
0313427976
Visiting Address: Gula stråket 2 B SU/Sahlgrenska , 413 45 Göteborg

About Viktor Sandblom

 Viktor Sandblom is currently working as a PhD-student in the Forssell-Aronsson Lab, within the Sahlgrenska Cancer Center. He has a Master of Science in Medical Physics/Radiation Physics. His field of research is radionuclide therapy, specifically focused on optimisation and possible ways to increase the therapeutic effect on tumour tissue. For more information please visit radfys.gu.se/FA-lab.

Latest publications

Molecular targeting of various human tumor cell lines with 177Lu-octreotate
Sofia Saadati, Johan Spetz, Viktor Sandblom, Emil Schüler, Ruth H. Palmer et al.
Annual Congress of the European Association of Nuclear Medicine , Conference contribution 2018
Conference contribution

In vitro screening for Lu-177-octreotate uptake in human tumor cell lines
Sofia Saadati, Johan Spetz, Viktor Sandblom, Emil Schüler, Ruth H. Palmer et al.
Cancerfondens Planeringsgrupp för Onkologisk Radionuklidterapi - Höstmöte 2017, Conference contribution 2017
Conference contribution

In vitro screening for Lu-177-octreotate uptake in human tumor cell lines
Johan Spetz, Viktor Sandblom, Emil Schüler, Ruth H. Palmer, Bengt Hallberg et al.
Cancerfondens Planeringsgrupp för Onkologisk Radionuklidterapi höstmöte 2017, Conference contribution 2017
Conference contribution

Binding and internalization of 177Lu-octreotate in human tumor cell lines of different origin
Sofia Saadati, Johan Spetz, Viktor Sandblom, Emil Schüler, Ruth H. Palmer et al.
63rd Annual Meeting of the Radiation Research Society, Cancun, Mexico, Conference contribution 2017
Conference contribution

Treatment of medullary thyroid cancer using a combination of radiation and gemcitabine
Viktor Sandblom, Johan Spetz, John Swanpalmer, Eva Forssell-Aronsson
62nd Annual International Meeting Radiation Research Society 2016. Big Island, Hawaii, USA, October 16-19, 2016, Conference contribution 2016
Conference contribution

Showing 1 - 10 of 29

2018

Molecular targeting of various human tumor cell lines with 177Lu-octreotate
Sofia Saadati, Johan Spetz, Viktor Sandblom, Emil Schüler, Ruth H. Palmer et al.
Annual Congress of the European Association of Nuclear Medicine , Conference contribution 2018
Conference contribution

2017

In vitro screening for Lu-177-octreotate uptake in human tumor cell lines
Sofia Saadati, Johan Spetz, Viktor Sandblom, Emil Schüler, Ruth H. Palmer et al.
Cancerfondens Planeringsgrupp för Onkologisk Radionuklidterapi - Höstmöte 2017, Conference contribution 2017
Conference contribution

In vitro screening for Lu-177-octreotate uptake in human tumor cell lines
Johan Spetz, Viktor Sandblom, Emil Schüler, Ruth H. Palmer, Bengt Hallberg et al.
Cancerfondens Planeringsgrupp för Onkologisk Radionuklidterapi höstmöte 2017, Conference contribution 2017
Conference contribution

Binding and internalization of 177Lu-octreotate in human tumor cell lines of different origin
Sofia Saadati, Johan Spetz, Viktor Sandblom, Emil Schüler, Ruth H. Palmer et al.
63rd Annual Meeting of the Radiation Research Society, Cancun, Mexico, Conference contribution 2017
Conference contribution

2016

Treatment of medullary thyroid cancer using a combination of radiation and gemcitabine
Viktor Sandblom, Johan Spetz, John Swanpalmer, Eva Forssell-Aronsson
62nd Annual International Meeting Radiation Research Society 2016. Big Island, Hawaii, USA, October 16-19, 2016, Conference contribution 2016
Conference contribution

Showing 1 - 10 of 29

Page Manager: Johan Spetz|Last update: 11/20/2013
Share:

The University of Gothenburg uses cookies to provide you with the best possible user experience. By continuing on this website, you approve of our use of cookies.  What are cookies?